Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,460 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer.
Moehler M, Eimermacher A, Siebler J, Höhler T, Wein A, Menges M, Flieger D, Junginger T, Geer T, Gracien E, Galle PR, Heike M. Moehler M, et al. Among authors: wein a. Br J Cancer. 2005 Jun 20;92(12):2122-8. doi: 10.1038/sj.bjc.6602649. Br J Cancer. 2005. PMID: 15942629 Free PMC article. Clinical Trial.
Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin.
Stickel F, Jüngert B, Brueckl V, Schirner I, Brueckl WM, Männlein G, Hegewald J, Mühldorfer S, Bittorf B, Hohenberger W, Hahn EG, Wein A. Stickel F, et al. Among authors: wein a. Anticancer Drugs. 2003 Oct;14(9):745-9. doi: 10.1097/00001813-200310000-00010. Anticancer Drugs. 2003. PMID: 14551509
Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study.
Hartmann JT, Oechsle K, Quietzsch D, Wein A, Hofheinz RD, Honecker F, Nehls O, Köhne CH, Käfer G, Kanz L, Bokemeyer C. Hartmann JT, et al. Among authors: wein a. Br J Cancer. 2003 Dec 1;89(11):2051-6. doi: 10.1038/sj.bjc.6601412. Br J Cancer. 2003. PMID: 14647137 Free PMC article. Clinical Trial.
Palliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC).
Link K, Happich K, Schirner I, Jüngert B, Brückl V, Männlein G, Brückl WM, Merkel S, Göhl J, Hohenberger W, Hahn EG, Wein A. Link K, et al. Among authors: wein a. Anticancer Res. 2004 Jan-Feb;24(1):385-91. Anticancer Res. 2004. PMID: 15015625 Free article. Clinical Trial.
Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Wagner AD, Buechner-Steudel P, Wein A, Schmalenberg H, Lindig U, Moehler M, Behrens R, Kleber G, Kuss O, Fleig WE. Wagner AD, et al. Among authors: wein a. Ann Oncol. 2007 Jan;18(1):82-87. doi: 10.1093/annonc/mdl340. Epub 2006 Oct 9. Ann Oncol. 2007. PMID: 17030546 Free article. Clinical Trial.
Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.
Boeck S, Hoehler T, Seipelt G, Mahlberg R, Wein A, Hochhaus A, Boeck HP, Schmid B, Kettner E, Stauch M, Lordick F, Ko Y, Geissler M, Schoppmeyer K, Kojouharoff G, Golf A, Neugebauer S, Heinemann V. Boeck S, et al. Among authors: wein a. Ann Oncol. 2008 Feb;19(2):340-7. doi: 10.1093/annonc/mdm467. Epub 2007 Oct 24. Ann Oncol. 2008. PMID: 17962204 Free article. Clinical Trial.
Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial.
Wolff K, Wein A, Reulbach U, Männlein G, Brückl V, Meier C, Ostermeier N, Schwab SA, Horbach T, Hohenberger W, Hahn EG, Boxberger F. Wolff K, et al. Among authors: wein a. Anticancer Drugs. 2009 Mar;20(3):165-73. doi: 10.1097/CAD.0b013e32831f8ec9. Anticancer Drugs. 2009. PMID: 19125117 Clinical Trial.
1,460 results